ERBB2 and metastatic neoplasm: Future studies should thus seek to develop patient-derived models from tumors that exhibit intrinsic or acquired resistance to enfortumab vedotin, in particular, models derived from metastatic sites as Nectin-4 and HER2 have been shown to be differentially expressed in patient-matched primary and metastatic tumor sites54,55.